The aim of the study was to investigate the efficacy of Leridip on chest pain, the profile of side effects, the patient compliance, the efficacy in preventing the major complications of ischemic heart disease, the efficacy on blood pressure reduction on treatment of hypertensive patients with stable angina pectoris. A prospective study was design between 2003 and 2004 that included chronic stable angina pectoris with hypertension patients. A sample of sixty patients has been investigated. Anti-ischemic effects assessed by stress test parameters showed that Leridip has antianginal effects. Leridip (Lercanidipine) in a single dose of 10-20 mg/day reduced the systolic blood pressure and the diastolic blood pressure over 24 hours with no influence on the heart rate. Leridip proved to improve the clinical symptomatology and the effort capacity of the hypertensive patients with stable angina pectoris.


Angina, Anti-ischemic effect, Calcium channel blockers, Hypertension.